Biopharma Quarterly Deal-Making Statistics, Q1 2017
A look at financing, M&A and alliance activity January–March 2017
Biopharma financing decreased by 29% in the first quarter of 2017; conversely, M&As set a record, reaching $61.9 billion. The largest alliance of the quarter involved the microbiome.
You may also be interested in...
The US approval of the targeted kinase inhibitor brigatinib seems to provide early validation of Takeda's recent acquisition of Ariad, but can the molecule carve its own niche amid intensifying same-class competition?
Forward Pharma is suspending all FP187 development pending the outcome of its legal interference appeal against Biogen – but analysts see little prospect of it overturning last month's decision that effectively allows Biogen's dimethyl fumarate-based drug Tecfidera to stay on the market with its own patent.
Buzz is growing over the potential of research on the microbiome to yield new therapeutics. Scrip asked pharma, academics and venture capitalists how long it might take to see results, what breakthroughs are needed and which therapeutic areas might benefit first. Vote to tell us what you think.